The 27th Annual Meeting of Japan Society of Gene and Cell Therapy (JSGCT2021)

Live Conference

DAY 1: Thursday, September 9

Room 1

Chairman’s Lecture11:20-11:50
Chairperson
Toya Ohashi(The Jikei University School of Medicine)
CL“Recent progress of oncolytic virus therapy using HSV-1”

Tomoki Todo(The Institute of Medical Science, The University of Tokyo)

Luncheon Seminar 112:00-12:50
Chairperson
Torayuki Okuyama(National Center for Child Health and Development)
LS1“Latest therapy trends for Lysosomal storage disorders ~from ERT to Gene Therapy~”

Yoshikatsu Eto(Advanced Clinical Research Center, Southern Tohoku Institute for Neuroscience /
The Jikei University School of Medicine)

ESGCT Special Lecture14:10-14:40
Chairperson
Yoshikatsu Eto(Advanced Clinical Research Center, Southern Tohoku Institute for Neuroscience /
The Jikei University School of Medicine)
SL1“Capsid-engineered Adeno-Associated Virus (AAV) vectors for in vivo Gene Therapy”

Hildegard Büning(President of ESGCT /Hannover Medical School, Germany)

Plenary Session 114:50-15:20
Chairpersons
Kazunori Aoki(National Cancer Center Research Institute)
Yoshikazu Yonemitsu(Graduate School of Medicine, Kyushu University)
PS1-1“Improving the in vivo gene targeting efficiency of liver-directed rAAV vector using the nucleotide analog class of ribonucleotide reductase inhibitors”

Shinnosuke Tsuji(Daiichi Sankyo Co., Ltd.)

PS1-2“LassoGraft Technology® allows rapid and simple generation of engineered AAV vectors with defined receptor dependency”

Junichi Takagi(Institute for Protein Research, Osaka University)

PS1-3“Elucidation of the mechanism of reovirus-mediated antifibrotic effects on liver fibrosis”

Ikuho Ishigami(Graduate School of Pharmaceutical Science, Osaka University)

Symposium 1: Genetic Disorders15:30-16:50
Chairpersons
Hiroshi Kobayashi(The Jikei University School of Medicine)
Makoto Otsu(Kitasato University School of Medicine)
S1-1“Progress of gene therapy for primary immunodeficiency diseases”

Toru Uchiyama(Division of Molecular Pathogenesis, Department of Human Genetics, National Center for Child Health and Development)

S1-2“Development of gene therapy targeting liver for congenital metabolic disorder based on novel AAV vector”

Kazuhiro Muramatsu(Department of Pediatrics / Division of Neurological Gene Therapy, Jichi Medical University)

S1-3“Hematopoietic stem cell gene therapy for mucopolysaccharidosis type II”

Yohta Shimada(Division of Gene Therapy, Research Center for Medical Sciences, The Jikei University School of Medicine)

S1-4“Gene therapy for hemophilia”

Tsukasa Ohmori(Department of Biochemistry, Jichi Medical University)

Symposium 2: Basics & Genome Editing17:00-18:20
Chairperson
Kohnosuke Mitani(Saitama Medical University)
S2-1“In vivo selection for the enhancement of cell and gene therapy of liver diseases”

Markus Grompe(Oregon Health and Science University, USA)

S2-2In vivo HSC genome editing”

Chang Li(University of Washington, Department of Medicine, Division of Medical Genetics, USA)

S2-3“Genome Editing for Duchene Muscular Dystrophy”

Charles A. Gersbach(Duke University, USA)

S2-4“On- and off-target effects of genome editing tools in clinically relevant human hematopoietic cells”

Toni Cathomen(Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Germany)

Evening Seminar 118:30-19:20
Chairperson
Yasufumi Kaneda(National University Corporation Osaka University)
ES1“Plasmid DNA-based Gene Therapy: From Vascular Regeneration to DNA Vaccines”

Ryuichi Morishita(Graduate School of Medicine, Osaka University)

Room 2

Luncheon Seminar 212:00-12:50
Chairperson
Junichi Mineno(Takara Bio Inc.)
LS“Biophysical characterization and quality control of AAV vectors”

Susumu Uchiyama(Department of Biotechnology, Graduate School of Engineering, Osaka University Manufacturing Technology Association of Biologics)

DAY 2: Friday, September 10

Room 1

Morning Seminar8:00-8:50
Chairperson
Makoto Otsu(Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine)
MS“Non-viral gene transfer based chimeric antigen receptor T cells for solid tumors”

Shigeki Yagyu(Department of Pediatrics, Kyoto Prefectural University of Medicine)

ASGCT Special Lectures9:00-10:00
Chairpersons
Tomoki Todo(The Institute of Medical Science, The University of Tokyo)
Noriyuki Kasahara(University of California, San Francisco, USA)
SL2-1“Intravenous oncolytic virotherapy using Voyager-V1 (VSV-IFNβ-NIS)”

Stephen J. Russell(Current President of ASGCT / Mayo Clinic and Vyriad, Rochester, Minnesota, USA )

SL2-2“TBD”

Beverly L. Davidson(President elect of ASGCT / Perelman School of Medicine of the University of Pennsylvania / Children's Hospital of Philadelphia, USA)

Symposium 3: Vector Development10:10-11:30
Chairpersons
Shin-ichi Muramatsu(Open Innovation Center, Jichi Medical University)
Hiroyuki Mizuguchi(Graduate School of Pharmaceutical Sciences, Osaka University)
S3-1“Development of the Next Generation of AAV Vectors for Human Gene Therapy”

Arun Srivastava(Division of Cellular and Molecular Therapy, Department of Pediatrics, Powell Gene Therapy Center, University of Florida College of Medicine, USA)

S3-2“Development of a novel oncolytic adenovirus based on adenovirus serotype 35”

Fuminori Sakurai(Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University)

S3-3“Lentiviral vector system for hematopoietic stem cell gene therapy”

Naoya Uchida(National Institutes of Health (NIH), USA / The Institute of Medical Science, The University of Tokyo)

S3-4“Development of an oncolytic herpes simplex virus expressing anti-VEGF antibody bevacizumab”

Hirotaka Ito(Division of Innovative Cancer Therapy, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo)

Takara Bio Award11:35-11:55
Chairperson
Tomoki Todo(The Institute of Medical Science, The University of Tokyo)
“Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles”

Yoshihiko Kakiuchi(Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences)

Luncheon Seminar 312:00-12:50
Chairperson
Takanori Yamagata(Department of Pediatrics, Jichi Medical University)
LS3“Current status and future perspective of AAV gene therapy for genetic neurological disorders”

Hitoshi Osaka(Department of Pediatrics, Jichi Medical University)

Symposium 4: Neurological Disorders13:00-14:20
Chairpersons
Takashi Okada(The Institute of Medical Science, The University of Tokyo)
Takanori Yamagata(Jichi Medical University)
S4-1“Treatments for outer retinal diseases”

Masayo Takahashi(Vision Care Inc. & Kobe City Eye Hospital)

S4-2“Gene Therapy Approaches using rAAV for the Treatment of Duchenne Muscular Dystrophy”

Hiromi Hayashita-Kinoh(Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo)

S4-3“Gene therapy of genetic neurological disorders”

Hitoshi Osaka(Department of Pediatrics, Jichi Medical University)

S4-4“Gene suppression therapy for Pelizaeus-Merzbacher disease using AAV harboring artificial miRNA: principals and problems”

Ken Inoue(Department of Mental Retardation & Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry)

Symposium 5: Clinical application14:30-15:50
Chairpersons
Toru Uchiyama(National Center for Child Health and Development)
Ryuichi Morishita(Department of Clinical Gene Therapy, Osaka University)
S5-1“Plasmid DNA-based Gene Therapy: From Collategene to DNA Vaccine”

Ryuichi Morishita(Department of Clinical Gene Therapy, Osaka University)

S5-2“Oncolytic Virus Therapy as Immunotherapy.”

Takashi Kojima(Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

S5-3“Clinical application of chimeric antigen receptor T-cell therapy for leukemia”

Motohiro Kato(Department of Pediatrics, The University of Tokyo)

S5-4“Clinical experiences of Onasemnogene abeparvovec treatment and worldwide clinical trials of gene therapy for child neurological diseases”

Takanori Yamagata(Department of Pediatrics, Jichi Medical University)

Symposium 6: Cancer16:00-17:20
Chairpersons
Yasutomo Nasu(Okayama University)
Hiroshi Fukuhara(Department of Urology, Kyorin University School of Medicine)
S6-1“Research and Development, Nonclinical Studies and First-In-Human and Phase Ⅰ/Ⅱ Clinical Trials of Conditionally Replicating Adenovirus Targeting and Treating with Multiple Factors (m-CRA) for Next-Generation Oncolytic Virus Immunotherapy”

Ken-ichiro Kosai(Department of Gene Therapy and Regenerative Medicine /
South Kyushu Center for Innovative Medical Research and Application /
Center for Innovative Therapy Research and Application, Kagoshima University Graduate School of Medicine and Dental Sciences /
Center for Clinical and Translational Research, Kagoshima University Hospital)

S6-2“Phase 1 clinical trial of a third-generation oncolytic HSV-1, G47∆ in patients with castration-resistant prostate cancer”

Hiroshi Fukuhara(Department of Urology, Kyorin University School of Medicine)

S6-3“CORE-001: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)”

James Burke(CG Oncology, USA)

S6-4“TBD”

Junichi Mineno(Takara Bio Inc.)

Evening Seminar217:30-18:20
Chairperson
Toya Ohashi(The Jikei University School of Nursing)
ES2“Present Status and Future Prospect of Novel Therapeutic Approach for Rare Genetic Diseases”

Torayuki Okuyama(National Center for Child Health and Development)

Plenary session 218:30-19:00
Chairpersons
Masatoshi Tagawa(Graduate School of Medicine, Chiba University)
Koichi Miyake(Nippon Medical School)
PS2-1“Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response and sensitivity to immune checkpoint blockade by remodeling the tumor microenvironment”

Motomu Nakatake(Department of Molecular Medicine, Graduate School of Medical Sciences, Tottori University)

PS2-2“Hematopoietic Stem Cell Gene Therapy Corrects Lysosomal Storage in CNS in Murine Model of GM1-gangliosidosis”

Toshiki Tsunogai(Department of Pediatrics, Jikei University School of Medicine)

PS2-3“Sustained fetal hemoglobin induction allowed by BCL11A interference with a truncated erythropoietin receptor”

Naoya Uchida(Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo / Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institutes (NHLBI)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), USA)

Room 2

Luncheon Seminar 412:00-12:50
Chairperson
Hariganeya Naohito(Nihon Pall Ltd.)
LS2-1“Practical use of single-use bioreactor technology in gene therapy – from Process development to Commercial manufacturing”

Horiuchi Kenichi(Nihon Pall Ltd.)

LS2-2“Scale-up of AAV production using ELEVECTA, the fully stable AAV production platform”

Juliana Coronel(CEVEC Pharmaceuticals GmbH)

Secretariat Office

c/o SK Apex Plan Co., Ltd.
SS Bldg. 5F, 1-8-6 Shintomi, Chuo-ku, Tokyo 104-0041, Japan
Tel: +81-3-3523-3722
Fax: +81-3-3523-3723
E-mail: info@skap.jp